Alpha Cognition prices $35M oversubscribed public offering at $6.25/share

Alpha Cognition Inc.

Gross proceeds of ~$35M from 5.6M shares (incl. pre-funded warrants) at $6.25 per share.
Offering was oversubscribed; led by premier healthcare-dedicated investor and large existing shareholders.
Expected to close Oct 2, 2025; underwriter has 30-day option to purchase up to 840K additional shares.
Net proceeds to accelerate commercial launch of ZUNVEYL (Benzgalantamine) for Alzheimer's disease.
Company expects total cash position of approximately $70 million following the closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.